Carnosine Side Effects: What Studies Report

What the published record contains — and what it does not

Carnosine is a naturally occurring dipeptide (β-alanyl-L-histidine) found in skeletal muscle and nervous tissue, and it is also sold as a dietary supplement in many markets. When readers search for carnosine side effects, the honest starting point is that the peer-reviewed literature on oral carnosine in humans is small, that most published carnosine work is mechanistic or animal-based, and that dedicated tolerability reporting is concentrated in a handful of sources.

This page summarises what published studies report about safety, tolerability and adverse events. It does not restate numerical doses where the cited papers' published scope does not supply them, and it does not extrapolate from animal or cell-model findings to human risk. Where data are absent, that absence is stated plainly rather than filled with inference. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decisions.

Human tolerability work: What Studies Report

A dedicated safety and tolerability study in healthy volunteers

The most directly relevant source in this collection is a 2025 Nutrients paper in which researchers described a safety, tolerability, plasma and brain concentration study of dietary carnosine supplementation in healthy human volunteers (Nutrients, 2025). The study's framing is itself informative: researchers treated basic tolerability and pharmacokinetic questions — how much carnosine appeared in plasma and whether it was measurable in brain — as open questions requiring a purpose-built protocol in healthy adults (Nutrients, 2025). That design signals how thin the prior human tolerability record was, because compounds with mature safety literatures do not usually require first-principles tolerability studies in healthy volunteers.

A randomized controlled trial in a metabolic population

A 2024 secondary analysis examined the effect of carnosine supplementation on musculoskeletal health in adults with prediabetes and type 2 diabetes, using data from a randomized controlled trial (Nutrients, 2024). Secondary analyses of this kind are important context for side-effect questions for two reasons. First, they confirm that at least one randomized, controlled human carnosine trial was completed in a clinical population rather than only in healthy athletes. Second, because the analysis was secondary, its outcomes were musculoskeletal rather than safety-focused, so it should not be read as a tolerability study even though it involved supervised supplementation in people with metabolic disease (Nutrients, 2024).

Amino acid supplement safety as a general framework

Carnosine is a dipeptide of two amino acids, so broader reviews of amino acid supplement safety are part of the relevant background. A 2022 review in Physiological Research examined side effects of amino acid supplements as its explicit subject (Physiological Research, 2022). Reviews of this type are useful because they group concerns by supplement class rather than treating every product as unique, and because they document how often adverse-effect reporting in supplement trials has been incomplete (Physiological Research, 2022). They do not, however, provide carnosine-specific adverse-event rates.

Sports-nutrition reviews add a second layer of context. A 2024 Nutrients review summarised the evidence base and practical considerations for widely used sport supplements (Nutrients, 2024). Carnosine sits adjacent to that literature because muscle carnosine content is a recurring topic in exercise physiology, but a review of sport supplements as a category does not establish adverse-event profiles for carnosine taken as an isolated dipeptide (Nutrients, 2024).

Zinc-L-carnosine is a different compound: What Studies Report

A frequent source of confusion is that safety information about zinc-L-carnosine (polaprezinc) is sometimes read as though it applied to carnosine. These are distinct products. A two-center randomized controlled trial evaluated zinc-L-carnosine (polaprezinc) in the management of infant regurgitation (Frontiers in Pediatrics, 2026). That trial studied a zinc-containing complex in infants, so its tolerability observations are specific to that formulation and that population and cannot be transferred to carnosine alone in adults (Frontiers in Pediatrics, 2026). Zinc itself has a well-documented tolerability profile that is separate from the dipeptide portion of the molecule, which is another reason the two literatures are not interchangeable.

Neurodevelopmental and combination-therapy research: What Studies Report

Carnosine has been discussed within broader reviews of supplement interventions in neurodevelopmental conditions. A 2022 systematic review and network meta-analysis compared pharmacological and dietary-supplement treatments studied in autism spectrum disorder (Molecular Autism, 2022). Network meta-analyses pool trials across many interventions, so readers interested in the tolerability of any single supplement arm need to check the arm-level data inside the review rather than treating its pooled conclusions as compound-specific safety findings (Molecular Autism, 2022).

Combination studies raise a related interpretive problem. Researchers reported on a triple therapy combining carnosine glycoside, edaravone and Xueshuantong in hemorrhagic cerebral infarction (American Journal of Translational Research, 2022). When three agents are administered together, any adverse events observed cannot be attributed to one component, and the carnosine derivative studied there is not identical to dietary carnosine (American Journal of Translational Research, 2022).

Preclinical mechanisms and what they can and cannot indicate

Iron scavenging in animal hearts

One mechanistic line of work is directly relevant to why safety questions remain open. Researchers reported that iron scavenging and suppression of collagen cross-linking underlay antifibrotic effects of carnosine in the heart with obesity (Frontiers in Pharmacology, 2023). Iron binding is a pharmacologically meaningful property, and the study described it as part of carnosine's mechanism rather than as an isolated laboratory curiosity (Frontiers in Pharmacology, 2023). What the published human record summarised here does not contain is any trial characterising how such interactions with iron biology behave in people over extended periods, so this remains an open question rather than a documented adverse effect.

Immune-facing mechanisms in a preprint

A 2025 preprint reported that carnosinylation of cardiac antigens attenuated immunogenic responses and improved function in failing hearts (bioRxiv, 2025). Two qualifications matter. The manuscript was posted as a preprint, meaning it had not completed peer review at the time of posting, and the work described modification of antigens and immune responses in a disease model rather than adverse events in humans (bioRxiv, 2025).

Cell models and metabolite panels

Two further study types often surface in carnosine searches and are frequently misread. Researchers used two human hepatocyte cell models to characterise metabolic and phenotypic changes induced by PFAS exposure (Environment International, 2024); cell-model metabolomics of this kind maps biochemical shifts in dishes of cells and cannot report tolerability in people. Similarly, an untargeted metabolomics analysis examined relationships between metabolite profiles and body mass in adolescents in cross-sectional and longitudinal designs (Metabolites, 2023). Observational metabolomics measures endogenous metabolites as correlates of a phenotype; it describes associations, not the consequences of supplementation (Metabolites, 2023).

Reading the evidence by study type

Where human data are absent

Stating absence accurately is part of a side-effect summary. Within the peer-reviewed sources collected here:

• Long-term human safety data are absent. No multi-year controlled trial of oral carnosine appears in this collection; the dedicated human work was a tolerability and concentration study in healthy volunteers (Nutrients, 2025).
• Pregnancy and lactation data are absent. No study here examined carnosine supplementation during pregnancy or breastfeeding.
• Pediatric data for carnosine itself are absent. The only pediatric randomized trial in this set studied zinc-L-carnosine in infant regurgitation, a different compound (Frontiers in Pediatrics, 2026).
• Drug-interaction studies are absent. The carnosine-containing human study in cerebral infarction used a three-agent combination, which is not an interaction study (Am J Transl Res, 2022).
• Renal and hepatic impairment data are absent. Class-level discussion of amino acid supplement side effects exists (Physiological Research, 2022), but carnosine-specific trials in organ impairment do not appear here.

Why carnosine's side-effect literature looks the way it does

Three structural features explain the gaps. First, carnosine is an endogenous dipeptide, so much of the research effort has gone into measuring native tissue concentrations and mechanisms rather than into supplement surveillance. Second, carnosine is rapidly handled by carnosinase enzymes in human plasma, which is why a human study needed to measure plasma and brain concentrations directly before tolerability could be interpreted meaningfully (Nutrients, 2025). Third, much of the translational interest has been in disease models — obesity-associated cardiac fibrosis (Frontiers in Pharmacology, 2023) and failing hearts (bioRxiv, 2025) — where efficacy signals, not adverse-event catalogues, were the reported endpoints.

How the literature is best read

1. Distinguish carnosine from zinc-L-carnosine, carnosine glycoside derivatives and beta-alanine before attributing any reported event to carnosine.
2. Check whether a paper's primary outcome was safety. Secondary analyses of randomized trials report the outcome they were designed for, such as musculoskeletal health in adults with prediabetes and type 2 diabetes (Nutrients, 2024).
3. Note publication status. Preprints such as the cardiac carnosinylation report had not completed peer review (bioRxiv, 2025).
4. Treat cell-model and metabolomics papers as biochemistry, not as tolerability evidence (Environment International, 2024).

Regulatory status is a separate matter from study findings: carnosine is marketed in various jurisdictions as a dietary supplement rather than as an approved drug for any indication, and dietary supplement frameworks do not require the pre-market adverse-event dossiers that pharmaceuticals do. That regulatory difference is one reason the tolerability literature summarised above is thinner than readers often expect.

For structured background on carnosine biochemistry, carnosinase handling and how muscle and brain carnosine are measured, the PeptideU carnosine course covers the underlying science; this page is limited to what studies report about safety, tolerability and adverse events. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decisions.

References

• Dietary Carnosine Supplementation in Healthy Human Volunteers: A Safety, Tolerability, Plasma and Brain Concentration Study (Nutrients, 2025)
• The Effect of Carnosine Supplementation on Musculoskeletal Health in Adults with Prediabetes and Type 2 Diabetes: A Secondary Analysis of a Randomized Controlled Trial (Nutrients, 2024)
• Side effects of amino acid supplements (Physiological Research, 2022)
• The Top 5 Can't-Miss Sport Supplements (Nutrients, 2024)
• Zinc-L-Carnosine (Polaprezinc) in managing infant regurgitation: a two-center randomized controlled trial (Frontiers in Pediatrics, 2026)
• Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis (Molecular Autism, 2022)
• Effects of the triple therapy of carnosine glycoside, edaravone, and Xueshuantong in hemorrhagic cerebral infarction (American Journal of Translational Research, 2022)
• Iron scavenging and suppression of collagen cross-linking underlie antifibrotic effects of carnosine in the heart with obesity (Frontiers in Pharmacology, 2023)
• Carnosinylation of Cardiac Antigens Attenuates Immunogenic Responses and Improves Function in Failing Hearts (bioRxiv, 2025)
• Metabolic and phenotypic changes induced by PFAS exposure in two human hepatocyte cell models (Environment International, 2024)
• Untargeted Metabolomics and Body Mass in Adolescents: A Cross-Sectional and Longitudinal Analysis (Metabolites, 2023)